Latest Insider Transactions at Aziyo Biologics, Inc. (AZYO)
This section provides a real-time view of insider transactions for Aziyo Biologics, Inc. (AZYO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AZIYO BIOLOGICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AZIYO BIOLOGICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 08
2022
|
Thomas Englese CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,390
+41.16%
|
-
|
|
Sep 08
2022
|
Jerome Riebman CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,104
-25.4%
|
$35,728
$7.3 P/Share
|
|
Sep 08
2022
|
Jerome Riebman CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,758
+42.35%
|
-
|
|
May 11
2022
|
Birchview Capital, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200
+0.01%
|
$1,000
$5.96 P/Share
|
|
Mar 10
2022
|
Thomas Englese CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
276
-4.01%
|
-
|
|
Mar 08
2022
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,288
+13.66%
|
-
|
|
Mar 08
2022
|
Jerome Riebman CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
782
+12.79%
|
-
|
|
Mar 08
2022
|
Ronald K. Lloyd PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,072
+11.36%
|
-
|
|
Mar 08
2022
|
Darryl Roberts EVP, OPERATIONS & PRODUCT DEV. |
BUY
Exercise of conversion of derivative security
|
Direct |
938
+21.98%
|
-
|
|
Mar 08
2022
|
Thomas Englese CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
938
+11.99%
|
-
|
|
Dec 14
2021
|
Thomas Englese CHIEF COMMERCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
4,580
+47.37%
|
$27,480
$6.1 P/Share
|
|
Dec 08
2021
|
High Cape Capital, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
412,735
+23.08%
|
$1,650,940
$4.24 P/Share
|
|
Sep 21
2021
|
High Cape Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,837,128
+25.17%
|
-
|
|
Sep 21
2021
|
High Cape Capital, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
2,837,128
+25.17%
|
-
|
|
May 11
2021
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
1,000
+30.3%
|
$11,000
$11.0 P/Share
|
|
May 10
2021
|
Matthew Ferguson CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
1,300
+50.0%
|
$14,300
$11.14 P/Share
|
|
May 07
2021
|
Ronald K. Lloyd PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
8,565
+15.21%
|
$94,215
$11.97 P/Share
|
|
Oct 13
2020
|
Ronald K. Lloyd PRESIDENT AND CEO |
BUY
Conversion of derivative security
|
Direct |
14,586
+50.0%
|
-
|
|
Oct 13
2020
|
High Cape Capital, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
441,176
+8.91%
|
$7,499,992
$17.0 P/Share
|
|
Oct 13
2020
|
High Cape Capital, L.P. Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
2,451
-0.06%
|
$12,255
$5.44 P/Share
|
|
Oct 13
2020
|
High Cape Capital, L.P. Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,655
+0.19%
|
$38,275
$5.44 P/Share
|
|
Oct 13
2020
|
High Cape Capital, L.P. Director |
BUY
Conversion of derivative security
|
Indirect |
4,062,451
+50.0%
|
-
|